Mega Genomics Limited(HK:6667)
HK$6.68+0.01 (+0.15%)
HK:6667
Mega Genomics Limited financials statements
HK$6.68
At close:+0.01 (+0.15%)
Want to see HK:6667 full AI Analyst Report?
Mega Genomics Limited (6667) Ratios
0 Followers
Mega Genomics Limited Ratios
HK:6667's free cash flow for Q2 2026 was ¥16.24M. For the 2026 fiscal year, HK:6667's free cash flow was decreased by ¥-40.05K and operating cash flow was ¥16.28M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | ― | 3.64 | 5.84 | 7.62 | 9.82 |
| Quick Ratio | ― | 3.44 | 5.80 | 7.58 | 9.77 |
| Cash Ratio | ― | 2.08 | 4.53 | 4.92 | 3.43 |
| Solvency Ratio | ― | 0.19 | 0.30 | -0.03 | 1.20 |
| Operating Cash Flow Ratio | ― | -0.08 | 1.43 | -0.09 | 0.44 |
| Short-Term Operating Cash Flow Coverage | ― | -7.94 | 85.61 | 0.00 | 0.00 |
| Net Current Asset Value | ― | ¥ 506.00M | ¥ 516.06M | ¥ 531.38M | ¥ 607.67M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | ― | 0.04 | 0.06 | 0.02 | 0.01 |
| Debt-to-Equity Ratio | ― | 0.05 | 0.08 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | ― | 0.05 | 0.07 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | ― | 0.03 | 0.03 | 0.00 | 0.00 |
| Financial Leverage Ratio | ― | 1.36 | 1.24 | 1.14 | 1.11 |
| Debt Service Coverage Ratio | ― | 12.86 | 15.25 | -2.25 | 14.44 |
| Interest Coverage Ratio | ― | 29.40 | 16.51 | 3.51 | 15.37 |
| Debt to Market Cap | ― | 0.01 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | ― | 0.16 | 0.23 | 0.06 | 0.09 |
| Net Debt to EBITDA | ― | -7.77 | -8.96 | 71.73 | -1.95 |
| Profitability Margins | |||||
| Gross Profit Margin | ― | 47.49% | 58.36% | 56.08% | 70.27% |
| EBIT Margin | ― | 13.83% | 24.65% | -14.20% | 43.34% |
| EBITDA Margin | ― | 20.10% | 34.65% | -3.72% | 49.19% |
| Operating Profit Margin | ― | 15.83% | 12.24% | 1.73% | 44.77% |
| Pretax Profit Margin | ― | 13.28% | 23.91% | -14.70% | 40.42% |
| Net Profit Margin | ― | 10.93% | 19.85% | -12.09% | 33.31% |
| Continuous Operations Profit Margin | ― | 10.93% | 19.85% | -12.09% | 33.31% |
| Net Income Per EBT | ― | 82.31% | 83.03% | 82.26% | 82.41% |
| EBT Per EBIT | ― | 83.90% | 195.29% | -847.57% | 90.29% |
| Return on Assets (ROA) | ― | 3.25% | 3.77% | -2.50% | 10.23% |
| Return on Equity (ROE) | ― | 4.42% | 4.66% | -2.85% | 11.38% |
| Return on Capital Employed (ROCE) | ― | 6.19% | 2.72% | 0.40% | 15.12% |
| Return on Invested Capital (ROIC) | ― | 5.03% | 2.21% | 0.33% | 12.35% |
| Return on Tangible Assets | ― | 3.25% | 3.78% | -2.50% | 10.24% |
| Earnings Yield | ― | 2.12% | 1.52% | -0.74% | 2.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | ― | 1.09 | 1.22 | 0.79 | 1.16 |
| Payables Turnover | ― | 0.94 | 1.59 | 1.84 | 2.41 |
| Inventory Turnover | ― | 3.29 | 14.29 | 18.25 | 21.47 |
| Fixed Asset Turnover | ― | 3.65 | 1.61 | 2.93 | 4.47 |
| Asset Turnover | ― | 0.30 | 0.19 | 0.21 | 0.31 |
| Working Capital Turnover Ratio | ― | 0.47 | 0.28 | 0.25 | 0.67 |
| Cash Conversion Cycle | ― | 57.39 | 95.27 | 284.72 | 179.22 |
| Days of Sales Outstanding | ― | 333.73 | 298.80 | 462.92 | 313.36 |
| Days of Inventory Outstanding | ― | 111.07 | 25.54 | 20.01 | 17.00 |
| Days of Payables Outstanding | ― | 387.41 | 229.07 | 198.21 | 151.14 |
| Operating Cycle | ― | 444.81 | 324.34 | 482.93 | 330.36 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | ― | -0.08 | 0.77 | -0.03 | 0.15 |
| Free Cash Flow Per Share | ― | -0.08 | 0.60 | -0.06 | 0.13 |
| Dividend Paid and CapEx Coverage Ratio | ― | -104.58 | 4.53 | -1.33 | 6.93 |
| Capital Expenditure Coverage Ratio | ― | -104.58 | 4.53 | -1.33 | 6.93 |
| Operating Cash Flow Coverage Ratio | ― | -0.56 | 3.37 | -0.63 | 2.65 |
| Operating Cash Flow to Sales Ratio | ― | -0.07 | 1.08 | -0.05 | 0.13 |
| Free Cash Flow Yield | ― | -1.31% | 6.46% | -0.51% | 0.89% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | ― | 49.75 | 66.66 | -134.41 | 37.59 |
| Price-to-Sales (P/S) Ratio | ― | 5.17 | 13.06 | 16.25 | 12.43 |
| Price-to-Book (P/B) Ratio | ― | 2.09 | 3.06 | 3.83 | 4.25 |
| Price-to-Free Cash Flow (P/FCF) Ratio | ― | -76.55 | 15.49 | -195.72 | 112.52 |
| Price-to-Operating Cash Flow Ratio | ― | -77.28 | 12.07 | -342.65 | 96.27 |
| Price-to-Earnings Growth (PEG) Ratio | ― | -1.22 | -0.25 | 1.10 | 2.07 |
| Enterprise Value Multiple | ― | 17.93 | 28.74 | -365.10 | 23.32 |
| Enterprise Value | ― | 890.69M | 1.51B | 1.98B | 2.72B |
| EV to EBITDA | ― | 17.93 | 28.74 | -365.10 | 23.32 |
| EV to Sales | ― | 3.60 | 9.96 | 13.58 | 11.47 |
| EV to Free Cash Flow | ― | -53.40 | 11.81 | -163.58 | 103.83 |
| EV to Operating Cash Flow | ― | -53.91 | 9.20 | -286.38 | 88.84 |
| Tangible Book Value Per Share | ― | 3.09 | 3.04 | 2.99 | 3.45 |
| Shareholders’ Equity Per Share | ― | 3.09 | 3.04 | 3.00 | 3.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | ― | 0.18 | 0.17 | 0.18 | 0.18 |
| Revenue Per Share | ― | 1.25 | 0.71 | 0.71 | 1.18 |
| Net Income Per Share | ― | 0.14 | 0.14 | -0.09 | 0.39 |
| Tax Burden | ― | 0.82 | 0.83 | 0.82 | 0.82 |
| Interest Burden | ― | 0.96 | 0.97 | 1.03 | 0.93 |
| Research & Development to Revenue | ― | 0.07 | 0.16 | 0.13 | 0.05 |
| SG&A to Revenue | ― | 0.25 | 0.50 | 0.53 | 0.11 |
| Stock-Based Compensation to Revenue | ― | 0.00 | 0.05 | 0.03 | 0.00 |
| Income Quality | ― | -0.50 | 5.45 | 0.32 | 0.32 |
Currency in CNY
